Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tongxiening for diarrhea-predominant irritable bowel syndrome
ChiCTR-IPR-15006415Phase 4Not yet recruiting
- Sponsor
- Xiyuan Hospital
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tongxiening in Diarrhea-predominant irritable bowel syndrome (IBS-D) (2 arms), sponsored by Xiyuan Hospital. Primary endpoints: IBS symptom severity score and Adequate relief. Planned start May 2015; status: not yet recruiting.
02
Drugs
tongxiening
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR-IPR-15006415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006415.